Showing results (41-50 of 280) with videos related to

Sort By:
Pageof 28
Current Opinion in Hematology|January 12, 2019
What are the most promising new agents in myelodysplastic syndromes?Namrata S Chandhok, Prajwal C Boddu, Steven D Gore, et al.
Blood Reviews|June 30, 2015
The evolving field of prognostication and risk stratification in MDS: Recent developments and future directionsEun-Ju Lee, Nikolai Podoltsev, Steven D Gore, et al.
Blood Reviews|October 18, 2016
Selecting initial treatment of acute myeloid leukaemia in older adultsNikolai A Podoltsev, Maximilian Stahl, Amer M Zeidan, et al.
Current Opinion in Hematology|January 10, 2015
Current state of prognostication and risk stratification in myelodysplastic syndromesAmer M Zeidan, Steven D Gore, Eric Padron, et al.
Cancer Chemotherapy and Pharmacology|December 26, 2006
Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPLTamer E Fandy, Douglas D Ross, Steven D Gore, et al.
Hematology. American Society of Hematology. Education Program|November 25, 2003
Myelodysplastic syndromeGhulam Mufti, Alan F List, Steven D Gore, et al.
Blood Reviews|September 29, 2020
Challenging the concept of de novo acute myeloid leukemia: Environmental and occupational leukemogens hiding in our midstRory M Shallis, Julian J Weiss, Nicole C Deziel, et al.
Blood Reviews|August 11, 2020
A clandestine culprit with critical consequences: Benzene and acute myeloid leukemiaRory M Shallis, Julian J Weiss, Nicole C Deziel, et al.
Future Oncology (London, England)|March 12, 2021
Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemiaSwapna Thota, Aram Oganesian, Mohammad Azab, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2004
State of the translational science: summary of Baltimore workshop on gene re-expression as a therapeutic target in cancer January 2003Arthur Zelent, Samuel Waxman, Michael Carducci, et al.
Pageof 28